注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Viridian Therapeutics Inc是一家專注於為患有嚴重疾病患者提供先進療法的生物技術公司。該公司致力於開發VRDN-001和VRDN-002兩種候選產品,以治療患有甲狀腺眼病(TED)的患者。TED是一種使人衰弱的自身免疫性疾病,會導致眼眶內的炎症和纖維化,從而導致複視、疼痛和潛在的失明。其主要候選產品VRDN-001是一種靶向胰島素樣生長因子-1受體(IGF-1R)的差異化人源化單克隆抗體,是一種經臨床和商業驗證的TED靶點。該公司已啟動VRDN-001的I/II期臨床試驗。其第二種候選產品VRDN-002是一種獨特的IGF-1R抗體,它結合了半衰期延長技術,旨在支持作為一種方便、低劑量的皮下注射劑,從而治療患有TED的患者。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Victor R. Ambros | - | - | Scientific Advisory Board Member |
Jeffery D. Molkentin | - | - | Scientific Advisory Board Member |
Eva van Rooij | - | - | Scientific Advisory Board Member |
Stefanie Dimmeler | - | - | Scientific Advisory Board Member |
Arlene M. Morris | 70 | 2018 | Independent Director |
Frank Slack | - | - | Scientific Advisory Board Member |
Tomas Kiselak | 35 | 2020 | Independent Chairperson of Board |
Peter Evan Harwin | 35 | 2020 | Independent Director |
Jennifer K. Moses | 47 | 2021 | Independent Director |
Stephen F. Mahoney | 53 | 2023 | CEO, President & Director |
Sarah Gheuens | 44 | 2023 | Independent Director |
Michael R. Bristow | 79 | - | Co-Founder & Member of the Scientific Advisory Board |
Marvin H. Caruthers | 84 | - | Co-Founder & Scientific Advisory Board Member |
Eric N. Olson | - | - | Co-Founder & Chairman of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核